BNGO: Rega marang dodolan Bionano
Bionano Genomics, Inc. (BNGO) has achieved a breakthrough in the diagnosis of rare pathologies by creating an optical DNA structure mapping system. The current P/S multiple reflects market expectations, with the 0.40 mark indicating the asset's current valuation. Business stability is supported by a neutral geopolitical status and equipment procurement via long-term grants, which mitigates the impact of macroeconomic shocks.
Rincian analitis perusahaan Bionano (BNGO)
- nilai pasar lan prakiraan target analis:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- indikator beban kredit lan likuiditas emiten:
Rasio Total Utang marang Ekuitas Bionano Genomics, Inc.|BNGO - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal Bionano Genomics|BNGO - Gunggung utang perusahaan|Utang marang nilai buku Bionano Genomics|BNGO - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Bionano Genomics|Rasio jangkoan perantara bionanogenomics.com
- indikator pendapatan resik lan kelipatan nilai:
BNGO - Bathi resik|Prakiraan bathi perusahaan Bionano Genomics, Inc.|BNGO - Rasio rega marang bathi|Rasio rega marang bathi mangsa ngarep Bionano Genomics|BNGO - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Bionano Genomics, Inc.|BNGO - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan Bionano Genomics|BNGO - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan bionanogenomics.com|BNGO - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep Bionano Genomics, Inc.
- data total pendapatan lan volume dodolan:
Analisis umum perusahaan:BNGO (Bionano Genomics, Inc.)
The P/S ratio determines the market value of a business relative to its annual revenue, allowing for an assessment of an asset's overvaluation in the absence of net profit. By analyzing the P/S chart, an investor compares market expectations with the monetization rates of innovations from the elite geneticists at Bionano Genomics, Inc. (BNGO), whose developments in genome mapping create the fundamental basis for future capitalization growth.
Pesaing Bionano Genomics, Inc.
TEM (Tempus AI, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Qiagen Group - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IONS|RGEN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Avidity Biosciences RNA|CRSP: Multiplikator P/S|Rasio kapitalisasi marang pendapatan WGS|RARE (Ultragenyx Pharma) - Multiplikator P/S|Multiplikator P/S Beam Therapeutics Inc.|Rasio rega marang pendapatan Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Rasio kapitalisasi marang pendapatan|10x Genomics Inc - Kapitalisasi marang pendapatan|NTLA (Intellia Therapeutics, Inc.) - Rasio rega marang dodolan|Stoke Corp - Multiplikator P/S|BLFS (BioLife) - Rasio kapitalisasi marang pendapatan|wavelifesciences.com (WVE) - Rasio rega marang pendapatan|MAZE - Koefisien rega marang pendapatan|SION (Sionna Therapeutics, Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan Prime Medicine Corp (PRME)|Multiplikator P/S TSHA|Multiplikator P/S uniQure N.V. (QURE)|Rasio rega marang pendapatan MeiraGTx Holdings plc MGTX|RGNX: Rasio kapitalisasi marang pendapatan|Solid Biosciences Inc - Multiplikator P/S|OCGN - Multiplikator P/S|PACB: Multiplikator P/S|BNTC - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Design Therapeutics, Inc.|RCKT: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan Korro Bio, Inc. KRRO|EDIT: Rasio kapitalisasi marang pendapatan|SLN - Rasio rega marang pendapatan|Multiplikator rega marang pendapatan ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Kapitalisasi marang pendapatan|Sangamo Therapeutics Inc. (SGMO) - Multiplikator P/S|Rasio rega marang pendapatan Nautilus Bio|Rega marang dodolan Metagenomi Therapeutics MGX|Rasio rega marang pendapatan Precision BioSciences (DTIL)|GBIO - Rega marang dodolan|Multiplikator P/S BOLD (Boundless Bio, Inc)|XCUR - Kapitalisasi marang pendapatan|IMNN - Rasio rega marang pendapatan|Rega marang dodolan Phio Pharmaceuticals Corp|MBIO: Multiplikator P/S|TransCode (RNAZ) - Multiplikator P/S|APDN (Applied DNA Corp) - Multiplikator P/S|BLUE: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan ImmunoPrecise (IPA)|OMGA - Rega marang dodolan|Rasio rega marang pendapatan Singular Genomics OMIC|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Unity Biotechnology, Inc - Rasio kapitalisasi pasar marang pendapatan
